Treating to Eliminate HCV: Case Discussion
  • CME
  • CE

In this video capture of a roundtable session from the 2019 CCO Hepatitis Annual Meeting, expert faculty provide a case-based analysis of important considerations and strategies for overcoming remaining challenges to treating all individuals with HCV infection, with a focus on several key populations: persons who inject drugs, persons who are incarcerated, women who are pregnant, and patients with genotype 3 HCV infection and cirrhosis.
Ira M. Jacobson, MD
Program Director
Jordan J. Feld, MD, MPH
Paul Y. Kwo, MD
Marion G. Peters, MD, FRACP
Nancy Reau, MD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Registered Nurses: 1.5 Nursing contact hours
Pharmacists: 1.5 contact hours (0.15 CEUs)
Released: August 1, 2019 Expiration: July 31, 2020
Multimedia Treating to Eliminate HCV: Case Discussion
This program is divided into short segments. After reviewing all segments, click the Claim Credit button to complete the CME/CE posttest and evaluation.
Introduction and Case 1: Starting HCV Therapy in PWID
Review a quick update on the changing epidemiology of HCV infection and the HCV care cascade in the US and consider care engagement and HCV management strategies for a person who injects drugs and is taken into jail before his positive HCV test results can be delivered to him.
Launch Introduction and Case 1: Starting HCV Therapy in PWID
Case 2: HCV Diagnosed During Pregnancy
Gain an understanding of the increasing prevalence of HCV infection among women who present for prenatal care and the resulting updated recommendations for universal HCV screening during pregnancy. Faculty also review and discuss guideline recommendations and new data on HCV management during pregnancy.
Launch Case 2: HCV Diagnosed During Pregnancy
Case 3: Treatment-Naive Patient With GT3 HCV Infection and Compensated Cirrhosis
Watch an engaging discussion on guideline recommendations and supporting data for optimizing treatment outcomes in treatment-naive patients with genotype 3 HCV infection and compensated cirrhosis.
Launch Case 3: Treatment-Naive Patient With GT3 HCV Infection and Compensated Cirrhosis

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Implement practical strategies for linking individuals from marginalized populations to HCV care when feasible
  • Integrate the results of clinical studies of approved HCV treatments into optimized patient management strategies for key underserved populations such as people who inject drugs
  • Apply key guidelines and study data to ensure appropriate HCV screening and management strategies during pregnancy

Acknowledgements

Provided by the Annenberg Center for Health Sciences at Eisenhower
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by educational grants from
AbbVie
Gilead Sciences
Janssen Therapeutics
Merck & Co., Inc.
ViiV Healthcare

Information on this Educational Activity

The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME/CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

Ira M. Jacobson, MD

Director of Hepatology
Department of Medicine
NYU School of Medicine
New York, New York

Ira M. Jacobson, MD, has disclosed that he has received consulting fees from AbbVie, Arrowhead, Assembly Biosciences, Bristol-Myers Squibb, Gilead Sciences, Intercept, Janssen, Merck, Novo Nordisk, Siemens, and Springbank and funds for research support from Assembly Biosciences, Bristol-Myers Squibb, Enanta, GENFIT, Gilead Sciences, and Janssen.

Faculty

Jordan J. Feld, MD, MPH

Associate Professor of Medicine
University of Toronto
Hepatologist
Toronto Centre for Liver Disease
Sandra Rotman Centre for Global Health
Toronto, Canada

Jordan J. Feld, MD, MPH, has disclosed that he has received consulting fees from Contravir, Enanta, and Roche and funds for research support from AbbVie, Gilead Sciences, and Janssen.
Paul Y. Kwo, MD

Professor of Medicine
Director of Hepatology
Stanford University School of Medicine
Palo Alto, California

Paul Y. Kwo, MD, has disclosed that he has received consulting fees from AbbVie, Conatus, Dova, Edigene, Eisai, Ferring, Gilead Sciences, Quest, and Surrozen; has received funds for research support from Allergan, Assembly, Gilead Sciences, La Jolla, and Target PharmaSolutions; and has ownership interest in Durect.
Marion G. Peters, MD, FRACP

Chief of Hepatology Research
Professor of Medicine, Gastroenterology
University of California, San Francisco
San Francisco, California

Marion G. Peters, MD, FRACP, has disclosed that her spouse is employed by Hoffmann-La Roche.
Nancy Reau, MD

Professor of Medicine
Chief,
Section of Hepatology
Associate Director, Solid Organ Transplantation
Richard B. Capps Chair of Hepatology
Rush University Medical Center
Chicago, Illinois

Nancy Reau, MD, has disclosed that she has received consulting fees from Abbott, AbbVie, Gilead Sciences, and Merck and funds for research support from Genfit, Intercept, and Shire.

Staff

Jennifer Blanchette, PhD

Senior Scientific Director

Jennifer Blanchette, PhD, has no relevant conflicts of interest to report.
Jenny Schulz, PhD

Director, Scientific Services

Jenny Schulz, PhD, has no relevant conflicts of interest to report.
Edward King, MA

Executive Vice President

Edward King, MA, has no relevant conflicts of interest to report.

The PIM planners and managers have nothing to disclose.

Charles E. Willis, Director of Continuing Education; Amanda Sewell, MBA, Manager of Continuing Education and Melissa Velasquez, Accreditation Specialist from the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Postgraduate Institute for Medicine (PIM), Clinical Care Options, and activity supporters do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, PIM, Clinical Care Options, and activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for hepatologists, gastroenterologists, infectious diseases clinicians, registered nurses, pharmacists, and other healthcare professionals involved in the care of patients with viral hepatitis.

Goal

The goal of this activity is to improve participants’ competence in addressing the most important and most current challenges in viral hepatitis management by providing a tightly focused update on recent advances and key clinical issues encountered in the clinic.

Physician Continuing Medical Education

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Accreditation Statement

Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Credit Designation

1.5 contact hours may be earned for successful completion of this activity.

Pharmacist Continuing Education

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation

This program is assigned ACPE Universal Activity 0797-9999-19-089-H01-P. This program is designated for up to 1.5 contact hours (0.15 CEUs) of continuing pharmacy education credit.

Type of Activity Application

For Pharmacists: Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 01, 2019, through July 31, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Expert commentary from Christopher Byrne and Dr. John Dillon on evaluating an HCV treatment as prevention (TasP) model for PWID in Tayside, Scotland

Christopher Byrne, BA (Hons), MSc John F. Dillon, MB BS, MRCP, MD, FRCP (Edin), FRCP (Lond) Released: September 4, 2019

Linda M. Spooner, PharmD, BCPS, FASHP, FCCP, provides insights on how pharmacist medication therapy management expertise can improve HCV care

Linda Spooner, PharmD, RPh, BCPS,, FASHP, FCCP Released: August 27, 2019

Audio commentary from Drs. Alessio Aghemo (Italy) and Karine Lacombe (France) with lessons from Europe on HCV treatment as prevention in PWID and others

Alessio Aghemo, MD, PhD Karine Lacombe, MD, PhD Released: August 27, 2019

CME/CE/CPE-certified video on strategies for simplifying HCV management with Jordan J. Feld, MD, MPH, from CCO Hepatitis Annual Meeting

Ira M. Jacobson, MD
Program Director
Jordan J. Feld, MD, MPH
Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.7 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: August 23, 2019 Expiration: August 22, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?